Aurinia Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurinia Pharmaceuticals Inc.
Industry executives note lessons learned from ‘fascinating’ approaches DOJ and states have taken in recent settlements, from restrictions on Novartis speaker programs to targeting McKinsey’s marketing advice. Chart includes details of 18 settlements since January 2020.
The Institute for Clinical and Economic Review raises concerns about the cost implications of companies obtaining extended market exclusivity by patenting the treatment protocol used for drugs in clinical trials.
Albert Roy, executive director of the clinical research arm of the Lupus Research Alliance, talked to Scrip about the outlook for lupus drug development.
GSK's Benlysta and Aurinia's Lupkynis for lupus nephritis are priced in line with the drug pricing watch dog's health benefit price benchmark ranges.
- Other Names / Subsidiaries
- Alberta Ltd.
- Isotechnika Pharma Inc.